Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29318392 | 0.90 | MAPT (0.41) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL24255256 | 0.81 | MAPT (0.42) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL19531676 | 0.79 | ALDH1A1 (0.43) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL24255521 | 0.79 | ALDH1A1 (0.43) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL26768229 | 0.78 | MAPT (0.42) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL24930081 | 0.78 | KDM4E (0.42) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL31714344 | 0.78 | MAPT (0.42) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL26482518 | 0.78 | MAPT (0.42) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL29318293 | 0.75 | MAPT (0.40) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL24163748 | 0.75 | KDM4E (0.42) | MAPTKDM4ENSD2ALDH1A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | MAPT 2035/4885KDM4E 2019/4885NSD2 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.